Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized Study of Imatinib Versus High Dose Interferon as Adjuvant Therapy in KIT-mutated Patients With Resected Melanoma

Next Previous
X
Search
Trial Profile

A Phase II Randomized Study of Imatinib Versus High Dose Interferon as Adjuvant Therapy in KIT-mutated Patients With Resected Melanoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary) ; Interferon alpha-2b
  • Indications Malignant melanoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Jun 2016 Results (n=48) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2013 Interim results (n=7) presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2013 Planned number of patients changed from 40 to 80, according to the abstract presented at the 49th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top